摘要
Ovarian cancer (OC) is the most lethal gynecological cancer due to the recurrence of drug-resistance. Cancer initiating cells (CICs) are proposed to be responsible for the aggressiveness of OC. The rarity and difficulty of in vitro long-term cultivation of CICs challenge the development of CIC-targeting therapeutics. Reprogramming cancer cells into induced cancer initiating cell (iCICs) could be an approach to solve these. Several inducible CICs have been acquired by activating the expression of stemness genes in different cancer cells. However, few reports have demonstrated the feasibility in OC.
原文 | 中文 |
---|---|
期刊 | BMC Cancer |
卷 | 22 |
發行號 | 1 |
DOIs | |
出版狀態 | 已發佈 - 2022 |
對外發佈 | 是 |